[Clinical evaluation of enantone in the treatment of prostate cancer].
OBJECTIVE
In order to improve the effect of hormone treatment for prostate cancer, a total of 17 such patients were treated with Enantone(chemical castration) from July 1990 to July 1992.


METHODS
In the control group, 16 evaluable patients who were followed for 3 to 5 years, PSA was determined with ELISA. Commercial kit was used for determination of T, LH and FSH. Prostate lesion and metastasis and patient's status was eximination in the follow-up.


RESULTS
Enantone was ableto suppress plasma testosterone concentration to the condition of castration during treatment (P < 0.01). PSA and other markers also responded well. Significant improvement in performance status, micturition problems and general well-being was reported.


CONCLUSIONS
The once a-month administration of Enantone combined with flutamide is effective in the management of advanced prostate cancer with acceptable side-effects.
Department of Urology, Beijing Hospital.
L
L
Zhang
D
D
Tao
S
S
Wang
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017430:Prostate-Specific Antigen; D016729:Leuprolide